Trial Profile
Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 05 Oct 2021 Planned End Date changed from 2 Mar 2024 to 1 Mar 2024.
- 05 Oct 2021 Planned primary completion date changed from 2 Dec 2022 to 1 Mar 2023.